Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study
Standard
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. / Camm, A John; Amarenco, Pierre; Haas, Sylvia; Bach, Miriam; Kirchhof, Paulus; Kuhls, Silvia; Lambelet, Marc; Turpie, Alexander G G; XANTUS Investigators.
In: CLIN CARDIOL, Vol. 43, No. 12, 12.2020, p. 1405-1413.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study
AU - Camm, A John
AU - Amarenco, Pierre
AU - Haas, Sylvia
AU - Bach, Miriam
AU - Kirchhof, Paulus
AU - Kuhls, Silvia
AU - Lambelet, Marc
AU - Turpie, Alexander G G
AU - XANTUS Investigators
N1 - © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
PY - 2020/12
Y1 - 2020/12
N2 - BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784).HYPOTHESIS: Because previous real-world studies have not reported gender-dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS study investigated the effect of gender on outcomes.METHODS: The centrally adjudicated outcomes were compared between genders. Primary outcomes were major bleeding and all-cause death. Secondary outcomes included symptomatic thromboembolic events. Multivariable Cox regression analysis was performed to assess the effect of risk factors on outcomes between genders.RESULTS: A total of 2765 female and 4016 male patients were included in the analysis. Baseline characteristics were generally similar. No nominally significant interaction between gender and risk factors for the study outcomes was observed. Rates of major bleeding, all-cause death and symptomatic thromboembolic events in patients with non-valvular AF receiving rivaroxaban for stroke prevention were similar in men and women; no significant differences in risk factors for these outcomes were observed between genders.CONCLUSIONS: Further research is needed to better characterize the relative importance of different risk factors on outcomes in men vs women and to determine whether gender differences exist in patients treated with non-vitamin K antagonist oral anticoagulants.
AB - BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784).HYPOTHESIS: Because previous real-world studies have not reported gender-dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS study investigated the effect of gender on outcomes.METHODS: The centrally adjudicated outcomes were compared between genders. Primary outcomes were major bleeding and all-cause death. Secondary outcomes included symptomatic thromboembolic events. Multivariable Cox regression analysis was performed to assess the effect of risk factors on outcomes between genders.RESULTS: A total of 2765 female and 4016 male patients were included in the analysis. Baseline characteristics were generally similar. No nominally significant interaction between gender and risk factors for the study outcomes was observed. Rates of major bleeding, all-cause death and symptomatic thromboembolic events in patients with non-valvular AF receiving rivaroxaban for stroke prevention were similar in men and women; no significant differences in risk factors for these outcomes were observed between genders.CONCLUSIONS: Further research is needed to better characterize the relative importance of different risk factors on outcomes in men vs women and to determine whether gender differences exist in patients treated with non-vitamin K antagonist oral anticoagulants.
KW - Aged
KW - Atrial Fibrillation/complications
KW - Dose-Response Relationship, Drug
KW - Europe/epidemiology
KW - Factor Xa Inhibitors/administration & dosage
KW - Female
KW - Humans
KW - Incidence
KW - Male
KW - Prospective Studies
KW - Risk Assessment/methods
KW - Risk Factors
KW - Rivaroxaban/administration & dosage
KW - Sex Distribution
KW - Sex Factors
KW - Survival Rate/trends
KW - Thromboembolism/epidemiology
U2 - 10.1002/clc.23452
DO - 10.1002/clc.23452
M3 - SCORING: Journal article
C2 - 32896928
VL - 43
SP - 1405
EP - 1413
JO - CLIN CARDIOL
JF - CLIN CARDIOL
SN - 0160-9289
IS - 12
ER -
